Dr. Andrew Lees

Fina Biosolutions

The magic behind conjugate vaccine development

Dr. Andrew Lees pulled a rabbit out of a hat when he founded Fina Biosolutions, a company dedicated to the provision of affordable conjugate vaccines. In this video, Lees, now CEO and Scientific Director of Fina Biosolutions, explains how the company has grown to offer a variety of bioconjugation and protein services and describes how the installation of PHCbi freezers has been instrumental in meeting the needs of his growing research team. Keep an eye out for an unexpected cameo from the part-time magician's fun-loving companion.



LIKE 5


Dr. Andrew Lees
Clinical Laboratory Diagnostics Biotherapeutics Drug Discovery

Dr. Andrew Lees

Biography

Dr. Andrew Lees, CEO and... More
Follow Andrew

Dr. Andrew Lees

Fina Biosolutions

Dr. Andrew Lees, CEO and Scientific Director of Fina Biosolutions, holds over 25 patents and is the author or co-author of more than 70 peer-reviewed papers. He holds a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Biophysics from The Johns Hopkins University. GlaxoSmithKline, the Serum Institute of India, the Chengdu Institute of Biological Products, and others all use conjugation chemistry (CDAP) developed by Dr. Lees in their S. pneumonia and meningococcal conjugate vaccines. He received the Johns Hopkins University Distinguished Alumni Award in 2019 for his efforts in making conjugate vaccines affordable for low-income countries.